Medical Cannabis: What Lessons Can Be Learned for the UK?

Article from Drug Science’s Head of Research – Dr Anne Schlag An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? Despite the legalization of medical cannabis in the UK in November 2018, patients still lack access to this medicine, with fewer than 10 NHS prescriptions having been written  …


Project Twenty21

Drug Science launched Europe’s first and biggest national medical cannabis registry, called Project Twenty21, on the 7th November 2019. Project TWENTY21 aims to enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical  …


Statement on the dangers posed by e-cigarettes

Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of  …


The Unintended Consequences of Prohibitionist Policies - Mephedrone

Mephedrone is the common name for 4-methylmethcathinone. This is a synthetic derivative of cathinone, first synthesized in 1929, and largely forgotten until the early 2000s when Israeli scientists working for an insecticide company started experimenting with cathinones as octopamine analogues to disrupt the brain activity of aphids so make them less damaging to plants. Mephedrone  …


UK General Election 2019 - Political party positions on drugs

With the 2019 general election fast approaching, a lot of media coverage will focus on each party’s Brexit policies. Drug Science would like to offer a different perspective, what do the six highest polling parties promise to do to address the UK’s failing drug policy. This is what each party has publicly announced relating to  …


Response to the Nature article: Moving from prison to PhD

There are fewer than ten empirical studies on the transition from prison to university so the article “Moving from Prison to PhD” is a step in the right direction to highlight this neglected and important topic. Globally, millions of individuals are arrested and charged with drug offences every year. Most of them will be scarred  …


Statement on the dangers posed by e-cigarettes

Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of  …


First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder (AUD). At this stage, eleven participants have completed the full 8-week MDMA-assisted  …


Groundhog decade not brave new world

Foreword by Professor David Nutt – “I was removed from my position as Chief Advisor of the Advisory Council on the Misuse of Drugs (ACMD) in October 2009. A decade later, UK drug policy has done nothing but go backwards. We are currently in a worse position now than we were 10 years ago. However,  …


Project Twenty21 – Scientific Oversight Board

Project Twenty21 is committed to scientific excellence and the development of independent scientific evidence. It is supported by a scientific oversight board, consisting of the following expertise: Professor David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI. Professor of Neuropsychopharmacology at Imperial College London. Professor Eileen Joyce MA, PhD, MB BChir, MRCP, FRCPsych Professor of Neuropsychiatry at  …